Abstract
Objective:
To evaluate the comparative effectiveness and safety of pharmacological and non-pharmacological management options for Atrial Fibrillation/Atrial Flutter with Rapid Ventricular Response (AFRVR) in patients with Acute Decompensated Heart Failure (ADHF) in the acute care setting.
Methods:
A systematic review of observational studies or randomized clinical trials of adult patients with AFRVR and concomitant ADHF in the ED, ICU, or step-down unit. The primary effectiveness outcome was successful rate or rhythm control. Safety outcomes were adverse events, such as symptomatic hypotension and venous thromboembolism.
Results:
A total of 6,577 unique articles were identified. Five studies met inclusion criteria: one randomized clinical trial in the inpatient setting, and four retrospective studies, two in the ED and the other three in the inpatient setting. In the randomized clinical trial of diltiazem vs placebo, 22 patients (100%) in the treatment group had a therapeutic response compared to 0/15 (0%) in the placebo group, with no significant safety differences between the two groups. For three of the observational studies, data were limited. One observation study showed no difference between metoprolol and diltiazem for successful rate control, but worsening heart failure symptoms occurred more frequently in those receiving diltiazem compared to metoprolol (19 patients (33%) vs 10 patients (15%), p = 0.019). A single study included electrical cardioversion (1 patient exposed with failure to convert to sinus rhythm) as non-pharmacological management. The overall risk of bias for included studies ranged from serious to critical. Missing data and heterogeneity of definitions for effectiveness and safety outcomes precluded the combination of results for quantitative meta-analysis.
Conclusions:
High-level evidence to inform clinical decision-making regarding effective and safe management of AFRVR in patients with ADHF in the acute care setting is lacking.
Full text
